Found: 37
Select item for more details and to access through your institution.
Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester): Effects Upon High-Sensitivity C-Reactive Protein and Lipid Parameters in Patients With Metabolic Syndrome.
- Published in:
- Metabolic Syndrome & Related Disorders, 2015, v. 13, n. 6, p. 239, doi. 10.1089/met.2014.0137
- By:
- Publication type:
- Article
Effects of Coadministered Ezetimibe Plus Fenofibrate in Mixed Dyslipidemic Patients with Metabolic Syndrome.
- Published in:
- Metabolic Syndrome & Related Disorders, 2011, v. 9, n. 2, p. 135, doi. 10.1089/met.2010.0068
- By:
- Publication type:
- Article
Anthropometric Measurements and Diabetes Mellitus: Clues to the “Pathogenic” and “Protective” Potential of Adipose Tissue.
- Published in:
- Metabolic Syndrome & Related Disorders, 2010, v. 8, n. 4, p. 307, doi. 10.1089/met.2009.0089
- By:
- Publication type:
- Article
Icosapent Ethyl Effects on Fatty Acid Profiles in Statin-Treated Patients With High Triglycerides: The Randomized, Placebo-controlled ANCHOR Study.
- Published in:
- Cardiology & Therapy, 2019, v. 8, n. 1, p. 79, doi. 10.1007/s40119-019-0131-8
- By:
- Publication type:
- Article
Long-term (52–78 weeks) treatment with colesevelam HCl added to metformin therapy in type 2 diabetes mellitus patients.
- Published in:
- Diabetes, Metabolic Syndrome & Obesity: Targets & Therapy, 2012, v. 5, p. 125, doi. 10.2147/DMSO.S32018
- By:
- Publication type:
- Article
Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control.
- Published in:
- Vascular Health & Risk Management, 2015, v. 11, p. 165, doi. 10.2147/VHRM.S70907
- By:
- Publication type:
- Article
Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control.
- Published in:
- 2015
- By:
- Publication type:
- journal article
MBX-8025, A Novel Peroxisome Proliferator Receptor-δ Agonist: Lipid and Other Metabolic Effects in Dyslipidemic Overweight Patients Treated with and without Atorvastatin.
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 2011, v. 96, n. 9, p. 2889, doi. 10.1210/jc.2011-1061
- By:
- Publication type:
- Article
Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: A post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 5, p. 868, doi. 10.1111/dom.14645
- By:
- Publication type:
- Article
Icosabutate, a Structurally Engineered Fatty Acid, Improves the Cardiovascular Risk Profile in Statin-Treated Patients with Residual Hypertriglyceridemia.
- Published in:
- Cardiology, 2016, v. 135, n. 1, p. 3, doi. 10.1159/000445047
- By:
- Publication type:
- Article
Effectiveness of a Novel ω-3 Krill Oil Agent in Patients With Severe Hypertriglyceridemia: A Randomized Clinical Trial.
- Published in:
- JAMA Network Open, 2022, v. 5, n. 1, p. e2141898, doi. 10.1001/jamanetworkopen.2021.41898
- By:
- Publication type:
- Article
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
- Published in:
- JAMA: Journal of the American Medical Association, 2024, v. 331, n. 1, p. 38, doi. 10.1001/jama.2023.24945
- By:
- Publication type:
- Article
Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study.
- Published in:
- Cardiovascular Diabetology, 2013, v. 12, n. 1, p. 1, doi. 10.1186/1475-2840-12-100
- By:
- Publication type:
- Article
Individualizing Treatment with Statin Therapy.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.
- Published in:
- European Journal of Preventive Cardiology, 2020, v. 27, n. 6, p. 593, doi. 10.1177/2047487319864671
- By:
- Publication type:
- Article
Evaluation of a New Formulation of Fenofibric Acid, ABT-335, Co-Administered with Statins: Study Design and Rationale of a Phase III Clinical Programme.
- Published in:
- Clinical Drug Investigation, 2008, v. 28, n. 10, p. 625, doi. 10.2165/00044011-200828100-00003
- By:
- Publication type:
- Article
Lowering low-density lipoprotein cholesterol levels in patients with type 2 diabetes mellitus.
- Published in:
- International Journal of General Medicine, 2014, v. 7, p. 355, doi. 10.2147/ijgm.s65148
- By:
- Publication type:
- Article
Effects of Omega-3-acid Ethyl Esters on LDL Particle Size in Subjects with Hypertriglyceridcmia Despite Statin Therapy.
- Published in:
- FASEB Journal, 2007, v. 21, n. 5, p. A108
- By:
- Publication type:
- Article
Efficacy and Safety of Alirocumab as Add-on Therapy in High-Cardiovascular-Risk Patients With Hypercholesterolemia Not Adequately Controlled With Atorvastatin (20 or 40 mg) or Rosuvastatin (10 or 20 mg): Design and Rationale of the ODYSSEY OPTIONS Studies
- Published in:
- Clinical Cardiology, 2014, v. 37, n. 10, p. 597, doi. 10.1002/clc.22327
- By:
- Publication type:
- Article
Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects.
- Published in:
- Clinical Cardiology, 2006, v. 29, n. 6, p. 268, doi. 10.1002/clc.4960290609
- By:
- Publication type:
- Article
Consistency of Extended-Release Niacin/ Laropiprant Effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 Ratio Across Patient Subgroups.
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
Consistency of Extended-Release Niacin/ Laropiprant Effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 Ratio Across Patient Subgroups.
- Published in:
- American Journal of Cardiovascular Drugs, 2012, v. 12, n. 3, p. 197, doi. 10.2165/11631530-000000000-00000
- By:
- Publication type:
- Article
Factors Associated With Enhanced Low-Density Lipoprotein Cholesterol Lowering With Bempedoic Acid.
- Published in:
- 2022
- By:
- Publication type:
- journal article
A Head-to-Head Comparison of a Free Fatty Acid Formulation of Omega-3 Pentaenoic Acids Versus Icosapent Ethyl in Adults With Hypertriglyceridemia: The ENHANCE-IT Study.
- Published in:
- Journal of the American Heart Association, 2022, v. 11, n. 6, p. 1, doi. 10.1161/JAHA.121.024176
- By:
- Publication type:
- Article
A Head-to-Head Comparison of a Free Fatty Acid Formulation of Omega-3 Pentaenoic Acids Versus Icosapent Ethyl in Adults With Hypertriglyceridemia: The ENHANCE-IT Study.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Alirocumab Treatment and Achievement of Non-High-Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Effectiveness of Rosuvastatin in LDL-C Lowering and National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Goal Attainment Compared to Other Statins Among Diabetes Patients.
- Published in:
- Diabetes, 2007, v. 56, p. A620
- By:
- Publication type:
- Article
Effect of Colesevelam HCl on Glycemic Control in Type 2 Diabetic Subjects Receiving Metformin Monotherapy.
- Published in:
- Diabetes, 2007, v. 56, p. A129
- By:
- Publication type:
- Article
Correction to: Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials.
- Published in:
- Cardiovascular Drugs & Therapy, 2018, v. 32, n. 2, p. 181, doi. 10.1007/s10557-018-6792-z
- By:
- Publication type:
- Article
Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials.
- Published in:
- Cardiovascular Drugs & Therapy, 2018, v. 32, n. 2, p. 175, doi. 10.1007/s10557-018-6784-z
- By:
- Publication type:
- Article
Current and Investigational Antiobesity Agents and Obesity Therapeutic Treatment Targets.
- Published in:
- Obesity (19307381), 2004, v. 12, n. 8, p. 1197, doi. 10.1038/oby.2004.151
- By:
- Publication type:
- Article
Fixed-dose combination ezetimibe+atorvastatin lowers LDL-C equivalent to co-administered components in randomized trials: use of a dose-response model.
- Published in:
- Fundamental & Clinical Pharmacology, 2015, v. 29, n. 2, p. 209, doi. 10.1111/fcp.12096
- By:
- Publication type:
- Article
Colesevelam, Ezetimibe, and Patients With Type 2 Diabetes Mellitus: Characteristics and Clinical Outcomes From a Health Care Database.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: A Randomized Clinical Trial.
- Published in:
- 2017
- By:
- Publication type:
- journal article
The Effects of Fenofibric Acid Alone and With Statins on the Prevalence of Metabolic Syndrome and Its Diagnostic Components in Patients With Mixed Dyslipidemia.
- Published in:
- Diabetes Care, 2010, v. 33, n. 9, p. 2113, doi. 10.2337/dc10-0357
- By:
- Publication type:
- Article
Licogliflozin, a Novel SGLT1 and 2 Inhibitor: Body Weight Effects in a Randomized Trial in Adults with Overweight or Obesity.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Canagliflozin: Effects in overweight and obese subjects without diabetes mellitus.
- Published in:
- Obesity (19307381), 2014, v. 22, n. 4, p. 1042, doi. 10.1002/oby.20663
- By:
- Publication type:
- Article